Cancer Treatments Using mRNA Technology Targeted as COVID Shots Sales Decline
BioNTech SE and Moderna, Inc., two leading pharmaceutical companies that developed the mRNA COVID-19 biological, are facing new financial and regulatory challenges as demand for COVID booster shots continues to fall and U.S. health policy changes reshape the vaccine market.1 Moderna cut its 2025 sales forecast to between $1.5 billion and $2.2 billion, down as […]
Moderna/Merck’s Combo Melanoma Cancer mRNA Therapeutic May Be Ready Next Year
The CEO of Moderna, Inc., Stephane Bancel, said last week that his company may introduce a new mRNA (messenger ribonucleic acid) biologic to treat melanoma cancer as early as 2025. Moderna has been working in partnership with Merck, Inc. to develop a mRNA-based shot that targets skin cancer cells. The product, mRNA-4157 (V940), would be […]